Ceretrophin Clinical Study

A double-blind, placebo controlled study examining the effects of Ceretrophin™ vs placebo on cognitive function, energy, state-of-mind and mood.

By Dr. Con Stough, Christina Kure, Jo Tarasuik and Luke Downey


BRAIN SCIENCES INSTITUTE
SWINBURNE UNIVERSITY, AUSTRALIA

Dr. Con Stough
BSI Director

Objective

Examine whether Ceretrophin™ enhances performance on tests assessing memory, attention, executive function, alertness, speed of information processing, mood, energy levels, stress and IQ.

Methodology

This study was a Phase III, double blind, placebo controlled exploratory trial with 150 healthy human participants that examined the neuropsychological effects of Ceretrophin™. It was expected that treatment with Ceretrophin™ would produce improvements in cognitive functioning, in particular memory, attention and executive processing. It was also anticipated that Ceretrophin™ would exert additional benefits in improving energy levels, anxiety, depression and stress.

Measures

  • The Cognitive Drug Research measure (CDR)
  • Inspection Time
  • UWIST Mood Adjective Checklist
  • Spielberger State-Trait Anxiety Inventory
  • The General Health Questionnaire (GHQ)
  • IQ: Raven Progressive Matrices

Results

Click Here to download the Ceretrophin™ Technical Report

Peer Review Publications

  • Psychopharmacology
  • Human Psychopharmacology
  • Neuroimage
  • Archives of General Psychiatry
  • Psychological Medicine
  • International Journal of Neuropsychopharmacology

Shop Now